Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
P-glycoprotein 1 (P-gp), encoded by the ABCB1 (MDR1) gene, is a well-characterized ATP-dependent efflux transporter. It is widely expressed in physiological barrier tissues, including the intestinal epithelium, the canalicular membrane of hepatocytes, the proximal tubules of the kidney, and the capillary endothelial cells of the blood-brain barrier. In these tissues, P-gp functions as a protective mechanism, pumping a broad range of structurally diverse xenobiotics, toxins, and therapeutic drugs out of cells and back into excretory pathways or the bloodstream, thereby limiting their systemic absorption and tissue penetration. In pathological contexts, particularly oncology, the overexpression of P-gp in cancer cells is a primary driver of multidrug resistance (MDR). By actively extruding chemotherapeutic agents such as anthracyclines, taxanes, and vinca alkaloids, P-gp significantly reduces intracellular drug accumulation and compromises treatment efficacy. Consequently, P-gp has been a major target for the development of chemosensitizers and efflux inhibitors. Additionally, genetic polymorphisms in the ABCB1 gene, such as the C3435T variant, are critical pharmacogenomic biomarkers that influence drug bioavailability, efficacy, and the risk of adverse drug-drug interactions.
Inhibition of ATP-dependent efflux, competitive substrate transport, and induction of transporter expression.
13 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on P-glycoprotein 1 (MDR1).